Chief Executive Officer
Ole Thastrup (1953) is co-founder of 2cureX. Prior to 2cureX Ole was Head of Carlsberg Biosector where he was responsible for Carlsberg's biomedical research. Before that, Ole was the scientific founder and Chief Scientific Officer of BioImage A/S (now Thermo Fischer BioImage) that was spun out of Novo Nordisk A/S. Ole is inventor of a large portfolio of issued patents. He has further assisted international venture funds in identification of attractive life science ventures. Ole is a shareholder in 2cureX.
Maarten van der Linden
Chief Business Officer
Maarten van der Linden (1969) joined 2cureX in 2017. He has 15 years of experience in the international Life Science and diagnostic industry. Maarten was recently Senior Director of Marketing for the EMEA region at Abbott Laboratories where he in three consecutive years outperformed the diagnostic market growth with a focus on Molecular Diagnostics and especially the oncology market. Before that, Maarten was Senior Director of Global marketing at Agilent Technologies in Denmark and Regional Business Manager for new Products at Merck, Sharp & Dohme covering multiple disease areas, including oncology. Maarten holds an Executive MBA Henley Business School, UK. Maarten is not a shareholder in 2cureX.
Carit J. Andersen
Chief Financial Officer
Carit Jacques Andersen (1964) joined 2cureX in 2019 as CFO. Carit holds an M.Sc. in Business Administration. Carit has over 25 years of experience in financial controlling and has previously been active in both the private and public sector. Previous assignments include the role as CFO at AstraZeneca A/S. Carit is not a shareholder in 2cureX.
Chief Medical Officer
Henrik Harling is an experienced surgeon within colorectal cancer. Harling is one of the founders of the Danish Colorectal Cancer Group (DCCG). Harling was Chairman from 1994 to 2010. DCCG is setting guidelines for colorectal cancer treatment and involved in deciding on implementation of new diagnostic technologies in Denmark.
Head of Project Management
Grith Hagel (1959) is co-founder of 2cureX. Grith has a comprehensive experience in developing and running drug screening campaigns. Grith is the inventor of several patents on advanced cell-based, high throughput screening technologies. Grith Hagel was also a co-founder of BioImage. Grith is a shareholder in 2cureX.
Managing director (2cureX GmbH)
Jürgen Kupper (1965) joined 2cureX in 2015. He began his career at Evotec AG in 1999. Jürgen’s previous experience include COO of Evotec Technologies, Product Leader for Live Cell Imaging at PerkinElmer and managing director of the diagnostic center at the University Medical Center Hamburg-Eppendorf (UKE). Jürgen holds a Ph.D. in Biophysics from Brandeis University, USA. Jürgen is not a shareholder in 2cureX.